Atypical adverse events in a real-world study of long-term immunomodulation for multiple sclerosis and neuromyelitis optica spectrum disorder
Within the confines of this real-world study, DMT administration emerged as generally well tolerated in MS, related demyelinating diseases and NMOSD. The identification of a limited number of atypical AEs, nevertheless, broadens the spectrum of potential complications associated with DMTs. Although weaker evidence for causal associations between drug exposure and observed AEs remains a limitation in observational studies without comparable control groups, this study underscores the value of real-world investigations in offering insights into the long-term safety of DMTs, particularly for rare events.
Authors
- Johannes Piepgras
- Stefan Bittner (ORCID: https://orcid.org/0000-0003-2179-3655)
- Felix Luessi (ORCID: https://orcid.org/0000-0003-4334-4199)
- Frauke Zipp (ORCID: https://orcid.org/0000-0002-1231-1928)
- A Kirschbaum
- Arda Civelek
Institutions
- Johannes Gutenberg University Mainz (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
Publication Details
- Journal
- Therapeutic Advances in Neurological Disorders
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1177/17562864251320206
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Hermann und Lilly Schilling-Stiftung für Medizinische Forschung
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung